Titre : Benzazépines

Benzazépines : Questions médicales fréquentes

Nom anglais: Benzazepines

Descriptor UI: D001552

Tree Number: D03.633.100.079

Termes MeSH sélectionnés :

Contrast Media

Questions fréquentes et termes MeSH associés

Diagnostic 5

#1

Comment diagnostiquer une dépendance aux benzazépines ?

Le diagnostic repose sur l'historique d'utilisation, les symptômes de sevrage et les comportements compulsifs.
Dépendance aux médicaments Benzodiazépines
#2

Quels tests sont utilisés pour évaluer l'usage des benzazépines ?

Des tests de dépistage de drogues et des évaluations psychologiques peuvent être utilisés.
Tests de dépistage Benzodiazépines
#3

Quels critères DSM sont liés aux benzazépines ?

Les critères DSM-5 pour le trouble d'usage de substances s'appliquent aux benzazépines.
Trouble d'usage de substances Benzodiazépines
#4

Comment évaluer les effets secondaires des benzazépines ?

L'évaluation se fait par l'observation des symptômes et l'historique médical du patient.
Effets secondaires Benzodiazépines
#5

Quels signes indiquent une surdose de benzazépines ?

Les signes incluent confusion, somnolence excessive, et dépression respiratoire.
Surdose Benzodiazépines

Symptômes 5

#1

Quels sont les symptômes d'une surconsommation de benzazépines ?

Les symptômes incluent somnolence, confusion, et troubles de la coordination.
Symptômes Benzodiazépines
#2

Comment se manifeste le sevrage des benzazépines ?

Le sevrage peut provoquer anxiété, insomnie, tremblements et convulsions.
Sevrage Benzodiazépines
#3

Quels effets à long terme des benzazépines ?

Les effets à long terme peuvent inclure des troubles cognitifs et une dépendance.
Effets à long terme Benzodiazépines
#4

Quels symptômes d'anxiété peuvent être soulagés par les benzazépines ?

Les benzazépines soulagent l'anxiété, les crises de panique et les troubles du sommeil.
Anxiété Benzodiazépines
#5

Les benzazépines causent-elles des troubles de la mémoire ?

Oui, elles peuvent entraîner des troubles de la mémoire, surtout à forte dose.
Troubles de la mémoire Benzodiazépines

Prévention 5

#1

Comment prévenir la dépendance aux benzazépines ?

Limiter la durée de prescription et surveiller l'utilisation sont des mesures préventives.
Prévention Dépendance aux médicaments
#2

Quelles sont les recommandations pour l'utilisation des benzazépines ?

Utiliser à la dose minimale efficace et pour la durée la plus courte possible.
Recommandations Benzodiazépines
#3

Comment éduquer les patients sur les benzazépines ?

Informer sur les risques, les effets secondaires et l'importance du suivi médical.
Éducation des patients Benzodiazépines
#4

Quels sont les risques d'auto-médication avec des benzazépines ?

L'auto-médication peut entraîner des surdoses, des dépendances et des interactions médicamenteuses.
Auto-médication Benzodiazépines
#5

Comment réduire l'usage des benzazépines dans la population ?

Promouvoir des alternatives thérapeutiques et sensibiliser aux risques associés.
Réduction de l'usage Benzodiazépines

Traitements 5

#1

Comment sont prescrites les benzazépines ?

Elles sont prescrites pour des périodes courtes, généralement moins de 4 semaines.
Prescription Benzodiazépines
#2

Quelles alternatives aux benzazépines pour l'anxiété ?

Les antidépresseurs, thérapies cognitives et techniques de relaxation sont des alternatives.
Antidépresseurs Anxiété
#3

Comment gérer une overdose de benzazépines ?

L'overdose nécessite une attention médicale immédiate, souvent avec des antidotes comme le flumazénil.
Overdose Benzodiazépines
#4

Les benzazépines sont-elles efficaces pour l'insomnie ?

Elles sont efficaces à court terme, mais peuvent entraîner une dépendance et des effets secondaires.
Insomnie Benzodiazépines
#5

Quel suivi est nécessaire lors de l'utilisation de benzazépines ?

Un suivi régulier est essentiel pour évaluer l'efficacité et surveiller les effets secondaires.
Suivi médical Benzodiazépines

Complications 5

#1

Quelles complications peuvent survenir avec les benzazépines ?

Les complications incluent la dépendance, les troubles cognitifs et les accidents liés à la somnolence.
Complications Benzodiazépines
#2

Les benzazépines augmentent-elles le risque de chutes ?

Oui, elles augmentent le risque de chutes, surtout chez les personnes âgées.
Chutes Benzodiazépines
#3

Comment les benzazépines affectent-elles la respiration ?

Elles peuvent déprimer le système respiratoire, surtout en cas de surdose.
Dépression respiratoire Benzodiazépines
#4

Les benzazépines peuvent-elles interagir avec d'autres médicaments ?

Oui, elles peuvent interagir avec des opioïdes, des antidépresseurs et d'autres sédatifs.
Interactions médicamenteuses Benzodiazépines
#5

Quels sont les effets des benzazépines sur la grossesse ?

Elles peuvent causer des malformations congénitales et des complications néonatales.
Grossesse Benzodiazépines

Facteurs de risque 5

#1

Quels facteurs augmentent le risque de dépendance aux benzazépines ?

Les antécédents de troubles de l'usage de substances et les troubles mentaux augmentent le risque.
Dépendance Benzodiazépines
#2

Les personnes âgées sont-elles plus à risque avec les benzazépines ?

Oui, elles sont plus sensibles aux effets sédatifs et aux risques de chutes.
Personnes âgées Benzodiazépines
#3

Comment l'usage prolongé de benzazépines affecte-t-il le risque ?

L'usage prolongé augmente le risque de dépendance et de troubles cognitifs.
Usage prolongé Benzodiazépines
#4

Quels facteurs psychologiques influencent l'usage des benzazépines ?

L'anxiété, la dépression et le stress peuvent inciter à l'usage des benzazépines.
Facteurs psychologiques Benzodiazépines
#5

Les interactions médicamenteuses augmentent-elles les risques ?

Oui, certaines interactions peuvent intensifier les effets sédatifs et augmenter le risque d'accidents.
Interactions médicamenteuses Benzodiazépines
{ "@context": "https://schema.org", "@graph": [ { "@type": "MedicalWebPage", "name": "Benzazépines : Questions médicales les plus fréquentes", "headline": "Benzazépines : Comprendre les symptômes, diagnostics et traitements", "description": "Guide complet et accessible sur les Benzazépines : explications, diagnostics, traitements et prévention. Information médicale validée destinée aux patients.", "datePublished": "2024-02-14", "dateModified": "2025-05-09", "inLanguage": "fr", "medicalAudience": [ { "@type": "MedicalAudience", "name": "Grand public", "audienceType": "Patient", "healthCondition": { "@type": "MedicalCondition", "name": "Benzazépines" }, "suggestedMinAge": 18, "suggestedGender": "unisex" }, { "@type": "MedicalAudience", "name": "Médecins", "audienceType": "Physician", "geographicArea": { "@type": "AdministrativeArea", "name": "France" } }, { "@type": "MedicalAudience", "name": "Chercheurs", "audienceType": "Researcher", "geographicArea": { "@type": "AdministrativeArea", "name": "International" } } ], "reviewedBy": { "@type": "Person", "name": "Dr Olivier Menir", "jobTitle": "Expert en Médecine", "description": "Expert en Médecine, Optimisation des Parcours de Soins et Révision Médicale", "url": "/static/pages/docteur-olivier-menir.html", "alumniOf": { "@type": "EducationalOrganization", "name": "Université Paris Descartes" } }, "isPartOf": { "@type": "MedicalWebPage", "name": "Composés hétérobicycliques", "url": "https://questionsmedicales.fr/mesh/D006574", "about": { "@type": "MedicalCondition", "name": "Composés hétérobicycliques", "code": { "@type": "MedicalCode", "code": "D006574", "codingSystem": "MeSH" }, "identifier": { "@type": "PropertyValue", "propertyID": "MeSH Tree", "value": "D03.633.100" } } }, "hasPart": [ { "@type": "MedicalWebPage", "name": "Benzodiazépines", "alternateName": "Benzodiazepines", "url": "https://questionsmedicales.fr/mesh/D001569", "about": { "@type": "MedicalCondition", "name": "Benzodiazépines", "code": { "@type": "MedicalCode", "code": "D001569", "codingSystem": "MeSH" }, "identifier": { "@type": "PropertyValue", "propertyID": "MeSH Tree", "value": "D03.633.100.079.080" } }, "hasPart": [ { "@type": "MedicalWebPage", "name": "Alprazolam", "alternateName": "Alprazolam", "url": "https://questionsmedicales.fr/mesh/D000525", "about": { "@type": "MedicalCondition", "name": "Alprazolam", "code": { "@type": "MedicalCode", "code": "D000525", "codingSystem": "MeSH" }, "identifier": { "@type": "PropertyValue", "propertyID": "MeSH Tree", "value": "D03.633.100.079.080.030" } } }, { "@type": "MedicalWebPage", "name": "Benzodiazépinones", "alternateName": "Benzodiazepinones", "url": "https://questionsmedicales.fr/mesh/D001570", "about": { "@type": "MedicalCondition", "name": "Benzodiazépinones", "code": { "@type": "MedicalCode", "code": "D001570", "codingSystem": "MeSH" }, "identifier": { "@type": "PropertyValue", "propertyID": "MeSH Tree", "value": "D03.633.100.079.080.070" } }, "hasPart": [ { "@type": "MedicalWebPage", "name": "Bromazépam", "alternateName": "Bromazepam", "url": "https://questionsmedicales.fr/mesh/D001960", "about": { "@type": "MedicalCondition", "name": "Bromazépam", "code": { "@type": "MedicalCode", "code": "D001960", "codingSystem": "MeSH" }, "identifier": { "@type": "PropertyValue", "propertyID": "MeSH Tree", "value": "D03.633.100.079.080.070.110" } } }, { "@type": "MedicalWebPage", "name": "Clonazépam", "alternateName": "Clonazepam", "url": "https://questionsmedicales.fr/mesh/D002998", "about": { "@type": "MedicalCondition", "name": "Clonazépam", "code": { "@type": "MedicalCode", "code": "D002998", "codingSystem": "MeSH" }, "identifier": { "@type": "PropertyValue", "propertyID": "MeSH Tree", "value": "D03.633.100.079.080.070.150" } } }, { "@type": "MedicalWebPage", "name": "Dévazépide", "alternateName": "Devazepide", "url": "https://questionsmedicales.fr/mesh/D020109", "about": { "@type": "MedicalCondition", "name": "Dévazépide", "code": { "@type": "MedicalCode", "code": "D020109", "codingSystem": "MeSH" }, "identifier": { "@type": "PropertyValue", "propertyID": "MeSH Tree", "value": "D03.633.100.079.080.070.200" } } }, { "@type": "MedicalWebPage", "name": "Diazépam", "alternateName": "Diazepam", "url": "https://questionsmedicales.fr/mesh/D003975", "about": { "@type": "MedicalCondition", "name": "Diazépam", "code": { "@type": "MedicalCode", "code": "D003975", "codingSystem": "MeSH" }, "identifier": { "@type": "PropertyValue", "propertyID": "MeSH Tree", "value": "D03.633.100.079.080.070.216" } }, "hasPart": [ { "@type": "MedicalWebPage", "name": "Nordazépam", "alternateName": "Nordazepam", "url": "https://questionsmedicales.fr/mesh/D003708", "about": { "@type": "MedicalCondition", "name": "Nordazépam", "code": { "@type": "MedicalCode", "code": "D003708", "codingSystem": "MeSH" }, "identifier": { "@type": "PropertyValue", "propertyID": "MeSH Tree", "value": "D03.633.100.079.080.070.216.500" } } } ] }, { "@type": "MedicalWebPage", "name": "Nordazépam", "alternateName": "Nordazepam", "url": "https://questionsmedicales.fr/mesh/D003708", "about": { "@type": "MedicalCondition", "name": "Nordazépam", "code": { "@type": "MedicalCode", "code": "D003708", "codingSystem": "MeSH" }, "identifier": { "@type": "PropertyValue", "propertyID": "MeSH Tree", "value": "D03.633.100.079.080.070.216.500" } } }, { "@type": "MedicalWebPage", "name": "Flumazénil", "alternateName": "Flumazenil", "url": "https://questionsmedicales.fr/mesh/D005442", "about": { "@type": "MedicalCondition", "name": "Flumazénil", "code": { "@type": "MedicalCode", "code": "D005442", "codingSystem": "MeSH" }, "identifier": { "@type": "PropertyValue", "propertyID": "MeSH Tree", "value": "D03.633.100.079.080.070.305" } } }, { "@type": "MedicalWebPage", "name": "Flunitrazépam", "alternateName": "Flunitrazepam", "url": "https://questionsmedicales.fr/mesh/D005445", "about": { "@type": "MedicalCondition", "name": "Flunitrazépam", "code": { "@type": "MedicalCode", "code": "D005445", "codingSystem": "MeSH" }, "identifier": { "@type": "PropertyValue", "propertyID": "MeSH Tree", "value": "D03.633.100.079.080.070.320" } } }, { "@type": "MedicalWebPage", "name": "Flurazépam", "alternateName": "Flurazepam", "url": "https://questionsmedicales.fr/mesh/D005479", "about": { "@type": "MedicalCondition", "name": "Flurazépam", "code": { "@type": "MedicalCode", "code": "D005479", "codingSystem": "MeSH" }, "identifier": { "@type": "PropertyValue", "propertyID": "MeSH Tree", "value": "D03.633.100.079.080.070.348" } } }, { "@type": "MedicalWebPage", "name": "Lorazépam", "alternateName": "Lorazepam", "url": "https://questionsmedicales.fr/mesh/D008140", "about": { "@type": "MedicalCondition", "name": "Lorazépam", "code": { "@type": "MedicalCode", "code": "D008140", "codingSystem": "MeSH" }, "identifier": { "@type": "PropertyValue", "propertyID": "MeSH Tree", "value": "D03.633.100.079.080.070.450" } } }, { "@type": "MedicalWebPage", "name": "Nitrazépam", "alternateName": "Nitrazepam", "url": "https://questionsmedicales.fr/mesh/D009567", "about": { "@type": "MedicalCondition", "name": "Nitrazépam", "code": { "@type": "MedicalCode", "code": "D009567", "codingSystem": "MeSH" }, "identifier": { "@type": "PropertyValue", "propertyID": "MeSH Tree", "value": "D03.633.100.079.080.070.565" } } }, { "@type": "MedicalWebPage", "name": "Oxazépam", "alternateName": "Oxazepam", "url": "https://questionsmedicales.fr/mesh/D010076", "about": { "@type": "MedicalCondition", "name": "Oxazépam", "code": { "@type": "MedicalCode", "code": "D010076", "codingSystem": "MeSH" }, "identifier": { "@type": "PropertyValue", "propertyID": "MeSH Tree", "value": "D03.633.100.079.080.070.663" } } }, { "@type": "MedicalWebPage", "name": "Pirenzépine", "alternateName": "Pirenzepine", "url": "https://questionsmedicales.fr/mesh/D010890", "about": { "@type": "MedicalCondition", "name": "Pirenzépine", "code": { "@type": "MedicalCode", "code": "D010890", "codingSystem": "MeSH" }, "identifier": { "@type": "PropertyValue", "propertyID": "MeSH Tree", "value": "D03.633.100.079.080.070.750" } } }, { "@type": "MedicalWebPage", "name": "Prazépam", "alternateName": "Prazepam", "url": "https://questionsmedicales.fr/mesh/D011222", "about": { "@type": "MedicalCondition", "name": "Prazépam", "code": { "@type": "MedicalCode", "code": "D011222", "codingSystem": "MeSH" }, "identifier": { "@type": "PropertyValue", "propertyID": "MeSH Tree", "value": "D03.633.100.079.080.070.784" } } }, { "@type": "MedicalWebPage", "name": "Témazépam", "alternateName": "Temazepam", "url": "https://questionsmedicales.fr/mesh/D013693", "about": { "@type": "MedicalCondition", "name": "Témazépam", "code": { "@type": "MedicalCode", "code": "D013693", "codingSystem": "MeSH" }, "identifier": { "@type": "PropertyValue", "propertyID": "MeSH Tree", "value": "D03.633.100.079.080.070.880" } } } ] }, { "@type": "MedicalWebPage", "name": "Bromazépam", "alternateName": "Bromazepam", "url": "https://questionsmedicales.fr/mesh/D001960", "about": { "@type": "MedicalCondition", "name": "Bromazépam", "code": { "@type": "MedicalCode", "code": "D001960", "codingSystem": "MeSH" }, "identifier": { "@type": "PropertyValue", "propertyID": "MeSH Tree", "value": "D03.633.100.079.080.070.110" } } }, { "@type": "MedicalWebPage", "name": "Clonazépam", "alternateName": "Clonazepam", "url": "https://questionsmedicales.fr/mesh/D002998", "about": { "@type": "MedicalCondition", "name": "Clonazépam", "code": { "@type": "MedicalCode", "code": "D002998", "codingSystem": "MeSH" }, "identifier": { "@type": "PropertyValue", "propertyID": "MeSH Tree", "value": "D03.633.100.079.080.070.150" } } }, { "@type": "MedicalWebPage", "name": "Dévazépide", "alternateName": "Devazepide", "url": "https://questionsmedicales.fr/mesh/D020109", "about": { "@type": "MedicalCondition", "name": "Dévazépide", "code": { "@type": "MedicalCode", "code": "D020109", "codingSystem": "MeSH" }, "identifier": { "@type": "PropertyValue", "propertyID": "MeSH Tree", "value": "D03.633.100.079.080.070.200" } } }, { "@type": "MedicalWebPage", "name": "Diazépam", "alternateName": "Diazepam", "url": "https://questionsmedicales.fr/mesh/D003975", "about": { "@type": "MedicalCondition", "name": "Diazépam", "code": { "@type": "MedicalCode", "code": "D003975", "codingSystem": "MeSH" }, "identifier": { "@type": "PropertyValue", "propertyID": "MeSH Tree", "value": "D03.633.100.079.080.070.216" } }, "hasPart": [ { "@type": "MedicalWebPage", "name": "Nordazépam", "alternateName": "Nordazepam", "url": "https://questionsmedicales.fr/mesh/D003708", "about": { "@type": "MedicalCondition", "name": "Nordazépam", "code": { "@type": "MedicalCode", "code": "D003708", "codingSystem": "MeSH" }, "identifier": { "@type": "PropertyValue", "propertyID": "MeSH Tree", "value": "D03.633.100.079.080.070.216.500" } } } ] }, { "@type": "MedicalWebPage", "name": "Nordazépam", "alternateName": "Nordazepam", "url": "https://questionsmedicales.fr/mesh/D003708", "about": { "@type": "MedicalCondition", "name": "Nordazépam", "code": { "@type": "MedicalCode", "code": "D003708", "codingSystem": "MeSH" }, "identifier": { "@type": "PropertyValue", "propertyID": "MeSH Tree", "value": "D03.633.100.079.080.070.216.500" } } }, { "@type": "MedicalWebPage", "name": "Flumazénil", "alternateName": "Flumazenil", "url": "https://questionsmedicales.fr/mesh/D005442", "about": { "@type": "MedicalCondition", "name": "Flumazénil", "code": { "@type": "MedicalCode", "code": "D005442", "codingSystem": "MeSH" }, "identifier": { "@type": "PropertyValue", "propertyID": "MeSH Tree", "value": "D03.633.100.079.080.070.305" } } }, { "@type": "MedicalWebPage", "name": "Flunitrazépam", "alternateName": "Flunitrazepam", "url": "https://questionsmedicales.fr/mesh/D005445", "about": { "@type": "MedicalCondition", "name": "Flunitrazépam", "code": { "@type": "MedicalCode", "code": "D005445", "codingSystem": "MeSH" }, "identifier": { "@type": "PropertyValue", "propertyID": "MeSH Tree", "value": "D03.633.100.079.080.070.320" } } }, { "@type": "MedicalWebPage", "name": "Flurazépam", "alternateName": "Flurazepam", "url": "https://questionsmedicales.fr/mesh/D005479", "about": { "@type": "MedicalCondition", "name": "Flurazépam", "code": { "@type": "MedicalCode", "code": "D005479", "codingSystem": "MeSH" }, "identifier": { "@type": "PropertyValue", "propertyID": "MeSH Tree", "value": "D03.633.100.079.080.070.348" } } }, { "@type": "MedicalWebPage", "name": "Lorazépam", "alternateName": "Lorazepam", "url": "https://questionsmedicales.fr/mesh/D008140", "about": { "@type": "MedicalCondition", "name": "Lorazépam", "code": { "@type": "MedicalCode", "code": "D008140", "codingSystem": "MeSH" }, "identifier": { "@type": "PropertyValue", "propertyID": "MeSH Tree", "value": "D03.633.100.079.080.070.450" } } }, { "@type": "MedicalWebPage", "name": "Nitrazépam", "alternateName": "Nitrazepam", "url": "https://questionsmedicales.fr/mesh/D009567", "about": { "@type": "MedicalCondition", "name": "Nitrazépam", "code": { "@type": "MedicalCode", "code": "D009567", "codingSystem": "MeSH" }, "identifier": { "@type": "PropertyValue", "propertyID": "MeSH Tree", "value": "D03.633.100.079.080.070.565" } } }, { "@type": "MedicalWebPage", "name": "Oxazépam", "alternateName": "Oxazepam", "url": "https://questionsmedicales.fr/mesh/D010076", "about": { "@type": "MedicalCondition", "name": "Oxazépam", "code": { "@type": "MedicalCode", "code": "D010076", "codingSystem": "MeSH" }, "identifier": { "@type": "PropertyValue", "propertyID": "MeSH Tree", "value": "D03.633.100.079.080.070.663" } } }, { "@type": "MedicalWebPage", "name": "Pirenzépine", "alternateName": "Pirenzepine", "url": "https://questionsmedicales.fr/mesh/D010890", "about": { "@type": "MedicalCondition", "name": "Pirenzépine", "code": { "@type": "MedicalCode", "code": "D010890", "codingSystem": "MeSH" }, "identifier": { "@type": "PropertyValue", "propertyID": "MeSH Tree", "value": "D03.633.100.079.080.070.750" } } }, { "@type": "MedicalWebPage", "name": "Prazépam", "alternateName": "Prazepam", "url": "https://questionsmedicales.fr/mesh/D011222", "about": { "@type": "MedicalCondition", "name": "Prazépam", "code": { "@type": "MedicalCode", "code": "D011222", "codingSystem": "MeSH" }, "identifier": { "@type": "PropertyValue", "propertyID": "MeSH Tree", "value": "D03.633.100.079.080.070.784" } } }, { "@type": "MedicalWebPage", "name": "Témazépam", "alternateName": "Temazepam", "url": "https://questionsmedicales.fr/mesh/D013693", "about": { "@type": "MedicalCondition", "name": "Témazépam", "code": { "@type": "MedicalCode", "code": "D013693", "codingSystem": "MeSH" }, "identifier": { "@type": "PropertyValue", "propertyID": "MeSH Tree", "value": "D03.633.100.079.080.070.880" } } }, { "@type": "MedicalWebPage", "name": "Chlordiazépoxyde", "alternateName": "Chlordiazepoxide", "url": "https://questionsmedicales.fr/mesh/D002707", "about": { "@type": "MedicalCondition", "name": "Chlordiazépoxyde", "code": { "@type": "MedicalCode", "code": "D002707", "codingSystem": "MeSH" }, "identifier": { "@type": "PropertyValue", "propertyID": "MeSH Tree", "value": "D03.633.100.079.080.150" } } }, { "@type": "MedicalWebPage", "name": "Clobazam", "alternateName": "Clobazam", "url": "https://questionsmedicales.fr/mesh/D000078306", "about": { "@type": "MedicalCondition", "name": "Clobazam", "code": { "@type": "MedicalCode", "code": "D000078306", "codingSystem": "MeSH" }, "identifier": { "@type": "PropertyValue", "propertyID": "MeSH Tree", "value": "D03.633.100.079.080.165" } } }, { "@type": "MedicalWebPage", "name": "Clorazépate dipotassique", "alternateName": "Clorazepate Dipotassium", "url": "https://questionsmedicales.fr/mesh/D003009", "about": { "@type": "MedicalCondition", "name": "Clorazépate dipotassique", "code": { "@type": "MedicalCode", "code": "D003009", "codingSystem": "MeSH" }, "identifier": { "@type": "PropertyValue", "propertyID": "MeSH Tree", "value": "D03.633.100.079.080.180" } } }, { "@type": "MedicalWebPage", "name": "Estazolam", "alternateName": "Estazolam", "url": "https://questionsmedicales.fr/mesh/D004949", "about": { "@type": "MedicalCondition", "name": "Estazolam", "code": { "@type": "MedicalCode", "code": "D004949", "codingSystem": "MeSH" }, "identifier": { "@type": "PropertyValue", "propertyID": "MeSH Tree", "value": "D03.633.100.079.080.250" } } }, { "@type": "MedicalWebPage", "name": "Médazépam", "alternateName": "Medazepam", "url": "https://questionsmedicales.fr/mesh/D008472", "about": { "@type": "MedicalCondition", "name": "Médazépam", "code": { "@type": "MedicalCode", "code": "D008472", "codingSystem": "MeSH" }, "identifier": { "@type": "PropertyValue", "propertyID": "MeSH Tree", "value": "D03.633.100.079.080.550" } } }, { "@type": "MedicalWebPage", "name": "Midazolam", "alternateName": "Midazolam", "url": "https://questionsmedicales.fr/mesh/D008874", "about": { "@type": "MedicalCondition", "name": "Midazolam", "code": { "@type": "MedicalCode", "code": "D008874", "codingSystem": "MeSH" }, "identifier": { "@type": "PropertyValue", "propertyID": "MeSH Tree", "value": "D03.633.100.079.080.575" } } }, { "@type": "MedicalWebPage", "name": "Olanzapine", "alternateName": "Olanzapine", "url": "https://questionsmedicales.fr/mesh/D000077152", "about": { "@type": "MedicalCondition", "name": "Olanzapine", "code": { "@type": "MedicalCode", "code": "D000077152", "codingSystem": "MeSH" }, "identifier": { "@type": "PropertyValue", "propertyID": "MeSH Tree", "value": "D03.633.100.079.080.738" } } }, { "@type": "MedicalWebPage", "name": "Triazolam", "alternateName": "Triazolam", "url": "https://questionsmedicales.fr/mesh/D014229", "about": { "@type": "MedicalCondition", "name": "Triazolam", "code": { "@type": "MedicalCode", "code": "D014229", "codingSystem": "MeSH" }, "identifier": { "@type": "PropertyValue", "propertyID": "MeSH Tree", "value": "D03.633.100.079.080.900" } } } ] }, { "@type": "MedicalWebPage", "name": "Diltiazem", "alternateName": "Diltiazem", "url": "https://questionsmedicales.fr/mesh/D004110", "about": { "@type": "MedicalCondition", "name": "Diltiazem", "code": { "@type": "MedicalCode", "code": "D004110", "codingSystem": "MeSH" }, "identifier": { "@type": "PropertyValue", "propertyID": "MeSH Tree", "value": "D03.633.100.079.150" } } }, { "@type": "MedicalWebPage", "name": "Fénoldopam", "alternateName": "Fenoldopam", "url": "https://questionsmedicales.fr/mesh/D018818", "about": { "@type": "MedicalCondition", "name": "Fénoldopam", "code": { "@type": "MedicalCode", "code": "D018818", "codingSystem": "MeSH" }, "identifier": { "@type": "PropertyValue", "propertyID": "MeSH Tree", "value": "D03.633.100.079.300" } } }, { "@type": "MedicalWebPage", "name": "Galantamine", "alternateName": "Galantamine", "url": "https://questionsmedicales.fr/mesh/D005702", "about": { "@type": "MedicalCondition", "name": "Galantamine", "code": { "@type": "MedicalCode", "code": "D005702", "codingSystem": "MeSH" }, "identifier": { "@type": "PropertyValue", "propertyID": "MeSH Tree", "value": "D03.633.100.079.525" } } }, { "@type": "MedicalWebPage", "name": "Ivabradine", "alternateName": "Ivabradine", "url": "https://questionsmedicales.fr/mesh/D000077550", "about": { "@type": "MedicalCondition", "name": "Ivabradine", "code": { "@type": "MedicalCode", "code": "D000077550", "codingSystem": "MeSH" }, "identifier": { "@type": "PropertyValue", "propertyID": "MeSH Tree", "value": "D03.633.100.079.801" } } }, { "@type": "MedicalWebPage", "name": "1-Phényl-2,3,4,5-tétrahydro-1H-3-benzazépine-7,8-diol", "alternateName": "2,3,4,5-Tetrahydro-7,8-dihydroxy-1-phenyl-1H-3-benzazepine", "url": "https://questionsmedicales.fr/mesh/D015647", "about": { "@type": "MedicalCondition", "name": "1-Phényl-2,3,4,5-tétrahydro-1H-3-benzazépine-7,8-diol", "code": { "@type": "MedicalCode", "code": "D015647", "codingSystem": "MeSH" }, "identifier": { "@type": "PropertyValue", "propertyID": "MeSH Tree", "value": "D03.633.100.079.838" } } }, { "@type": "MedicalWebPage", "name": "Tolvaptan", "alternateName": "Tolvaptan", "url": "https://questionsmedicales.fr/mesh/D000077602", "about": { "@type": "MedicalCondition", "name": "Tolvaptan", "code": { "@type": "MedicalCode", "code": "D000077602", "codingSystem": "MeSH" }, "identifier": { "@type": "PropertyValue", "propertyID": "MeSH Tree", "value": "D03.633.100.079.875" } } } ], "about": { "@type": "MedicalCondition", "name": "Benzazépines", "alternateName": "Benzazepines", "code": { "@type": "MedicalCode", "code": "D001552", "codingSystem": "MeSH" } }, "author": [ { "@type": "Person", "name": "Bernhard Wünsch", "url": "https://questionsmedicales.fr/author/Bernhard%20W%C3%BCnsch", "affiliation": { "@type": "Organization", "name": "Institute of Pharmaceutical and Medicinal Chemistry, University of Münster, Münster, Germany." } }, { "@type": "Person", "name": "Dirk Schepmann", "url": "https://questionsmedicales.fr/author/Dirk%20Schepmann", "affiliation": { "@type": "Organization", "name": "Institute of Pharmaceutical and Medicinal Chemistry, University of Münster, Corrensstr. 48, 48149, Münster, Germany." } }, { "@type": "Person", "name": "Simon M Ametamey", "url": "https://questionsmedicales.fr/author/Simon%20M%20Ametamey", "affiliation": { "@type": "Organization", "name": "Institute of Pharmaceutical Sciences, ETH Zurich, Zurich, Switzerland simon.ametamey@pharma.ethz.ch." } }, { "@type": "Person", "name": "Nadine Ritter", "url": "https://questionsmedicales.fr/author/Nadine%20Ritter", "affiliation": { "@type": "Organization", "name": "Institute for Genetics of Heart Diseases (IfGH), Department of Cardiovascular Medicine, University Hospital Münster, 48149, Münster, Germany. nadine.ritter@uni-muenster.de." } }, { "@type": "Person", "name": "Guiscard Seebohm", "url": "https://questionsmedicales.fr/author/Guiscard%20Seebohm", "affiliation": { "@type": "Organization", "name": "Institute for Genetics of Heart Diseases (IfGH), Department of Cardiovascular Medicine, University Hospital Münster, 48149, Münster, Germany." } } ], "citation": [ { "@type": "ScholarlyArticle", "name": "Radiographic Contrast Media and the Kidney.", "datePublished": "2022-07-01", "url": "https://questionsmedicales.fr/article/35777831", "identifier": { "@type": "PropertyValue", "propertyID": "DOI", "value": "10.2215/CJN.16311221" } }, { "@type": "ScholarlyArticle", "name": "[Contrast Media Toxicity and Its Prevention].", "datePublished": "2023-10-26", "url": "https://questionsmedicales.fr/article/38010244", "identifier": { "@type": "PropertyValue", "propertyID": "DOI", "value": null } }, { "@type": "ScholarlyArticle", "name": "Contrast media volume reduction with the DyeVert", "datePublished": "2023-09-05", "url": "https://questionsmedicales.fr/article/37668067", "identifier": { "@type": "PropertyValue", "propertyID": "DOI", "value": "10.1002/ccd.30809" } }, { "@type": "ScholarlyArticle", "name": "Iodinated Contrast Media Conservation Measures During a Global Shortage: Effect on Contrast Media Use at a Large Health System.", "datePublished": "2022-06-22", "url": "https://questionsmedicales.fr/article/35731095", "identifier": { "@type": "PropertyValue", "propertyID": "DOI", "value": "10.2214/AJR.22.28080" } }, { "@type": "ScholarlyArticle", "name": "Strategies for calculating contrast media dose for chest CT.", "datePublished": "2023-06-12", "url": "https://questionsmedicales.fr/article/37303003", "identifier": { "@type": "PropertyValue", "propertyID": "DOI", "value": "10.1186/s41747-023-00345-w" } } ], "breadcrumb": { "@type": "BreadcrumbList", "itemListElement": [ { "@type": "ListItem", "position": 1, "name": "questionsmedicales.fr", "item": "https://questionsmedicales.fr" }, { "@type": "ListItem", "position": 2, "name": "Composés hétérocycliques", "item": "https://questionsmedicales.fr/mesh/D006571" }, { "@type": "ListItem", "position": 3, "name": "Composés hétérocycliques à cycles fusionnés", "item": "https://questionsmedicales.fr/mesh/D000072471" }, { "@type": "ListItem", "position": 4, "name": "Composés hétérobicycliques", "item": "https://questionsmedicales.fr/mesh/D006574" }, { "@type": "ListItem", "position": 5, "name": "Benzazépines", "item": "https://questionsmedicales.fr/mesh/D001552" } ] } }, { "@type": "MedicalWebPage", "name": "Article complet : Benzazépines - Questions et réponses", "headline": "Questions et réponses médicales fréquentes sur Benzazépines", "description": "Une compilation de questions et réponses structurées, validées par des experts médicaux.", "datePublished": "2025-05-10", "inLanguage": "fr", "hasPart": [ { "@type": "MedicalWebPage", "name": "Diagnostic", "headline": "Diagnostic sur Benzazépines", "description": "Comment diagnostiquer une dépendance aux benzazépines ?\nQuels tests sont utilisés pour évaluer l'usage des benzazépines ?\nQuels critères DSM sont liés aux benzazépines ?\nComment évaluer les effets secondaires des benzazépines ?\nQuels signes indiquent une surdose de benzazépines ?", "url": "https://questionsmedicales.fr/mesh/D001552?mesh_terms=Contrast+Media#section-diagnostic" }, { "@type": "MedicalWebPage", "name": "Symptômes", "headline": "Symptômes sur Benzazépines", "description": "Quels sont les symptômes d'une surconsommation de benzazépines ?\nComment se manifeste le sevrage des benzazépines ?\nQuels effets à long terme des benzazépines ?\nQuels symptômes d'anxiété peuvent être soulagés par les benzazépines ?\nLes benzazépines causent-elles des troubles de la mémoire ?", "url": "https://questionsmedicales.fr/mesh/D001552?mesh_terms=Contrast+Media#section-symptômes" }, { "@type": "MedicalWebPage", "name": "Prévention", "headline": "Prévention sur Benzazépines", "description": "Comment prévenir la dépendance aux benzazépines ?\nQuelles sont les recommandations pour l'utilisation des benzazépines ?\nComment éduquer les patients sur les benzazépines ?\nQuels sont les risques d'auto-médication avec des benzazépines ?\nComment réduire l'usage des benzazépines dans la population ?", "url": "https://questionsmedicales.fr/mesh/D001552?mesh_terms=Contrast+Media#section-prévention" }, { "@type": "MedicalWebPage", "name": "Traitements", "headline": "Traitements sur Benzazépines", "description": "Comment sont prescrites les benzazépines ?\nQuelles alternatives aux benzazépines pour l'anxiété ?\nComment gérer une overdose de benzazépines ?\nLes benzazépines sont-elles efficaces pour l'insomnie ?\nQuel suivi est nécessaire lors de l'utilisation de benzazépines ?", "url": "https://questionsmedicales.fr/mesh/D001552?mesh_terms=Contrast+Media#section-traitements" }, { "@type": "MedicalWebPage", "name": "Complications", "headline": "Complications sur Benzazépines", "description": "Quelles complications peuvent survenir avec les benzazépines ?\nLes benzazépines augmentent-elles le risque de chutes ?\nComment les benzazépines affectent-elles la respiration ?\nLes benzazépines peuvent-elles interagir avec d'autres médicaments ?\nQuels sont les effets des benzazépines sur la grossesse ?", "url": "https://questionsmedicales.fr/mesh/D001552?mesh_terms=Contrast+Media#section-complications" }, { "@type": "MedicalWebPage", "name": "Facteurs de risque", "headline": "Facteurs de risque sur Benzazépines", "description": "Quels facteurs augmentent le risque de dépendance aux benzazépines ?\nLes personnes âgées sont-elles plus à risque avec les benzazépines ?\nComment l'usage prolongé de benzazépines affecte-t-il le risque ?\nQuels facteurs psychologiques influencent l'usage des benzazépines ?\nLes interactions médicamenteuses augmentent-elles les risques ?", "url": "https://questionsmedicales.fr/mesh/D001552?mesh_terms=Contrast+Media#section-facteurs de risque" } ] }, { "@type": "FAQPage", "mainEntity": [ { "@type": "Question", "name": "Comment diagnostiquer une dépendance aux benzazépines ?", "position": 1, "acceptedAnswer": { "@type": "Answer", "text": "Le diagnostic repose sur l'historique d'utilisation, les symptômes de sevrage et les comportements compulsifs." } }, { "@type": "Question", "name": "Quels tests sont utilisés pour évaluer l'usage des benzazépines ?", "position": 2, "acceptedAnswer": { "@type": "Answer", "text": "Des tests de dépistage de drogues et des évaluations psychologiques peuvent être utilisés." } }, { "@type": "Question", "name": "Quels critères DSM sont liés aux benzazépines ?", "position": 3, "acceptedAnswer": { "@type": "Answer", "text": "Les critères DSM-5 pour le trouble d'usage de substances s'appliquent aux benzazépines." } }, { "@type": "Question", "name": "Comment évaluer les effets secondaires des benzazépines ?", "position": 4, "acceptedAnswer": { "@type": "Answer", "text": "L'évaluation se fait par l'observation des symptômes et l'historique médical du patient." } }, { "@type": "Question", "name": "Quels signes indiquent une surdose de benzazépines ?", "position": 5, "acceptedAnswer": { "@type": "Answer", "text": "Les signes incluent confusion, somnolence excessive, et dépression respiratoire." } }, { "@type": "Question", "name": "Quels sont les symptômes d'une surconsommation de benzazépines ?", "position": 6, "acceptedAnswer": { "@type": "Answer", "text": "Les symptômes incluent somnolence, confusion, et troubles de la coordination." } }, { "@type": "Question", "name": "Comment se manifeste le sevrage des benzazépines ?", "position": 7, "acceptedAnswer": { "@type": "Answer", "text": "Le sevrage peut provoquer anxiété, insomnie, tremblements et convulsions." } }, { "@type": "Question", "name": "Quels effets à long terme des benzazépines ?", "position": 8, "acceptedAnswer": { "@type": "Answer", "text": "Les effets à long terme peuvent inclure des troubles cognitifs et une dépendance." } }, { "@type": "Question", "name": "Quels symptômes d'anxiété peuvent être soulagés par les benzazépines ?", "position": 9, "acceptedAnswer": { "@type": "Answer", "text": "Les benzazépines soulagent l'anxiété, les crises de panique et les troubles du sommeil." } }, { "@type": "Question", "name": "Les benzazépines causent-elles des troubles de la mémoire ?", "position": 10, "acceptedAnswer": { "@type": "Answer", "text": "Oui, elles peuvent entraîner des troubles de la mémoire, surtout à forte dose." } }, { "@type": "Question", "name": "Comment prévenir la dépendance aux benzazépines ?", "position": 11, "acceptedAnswer": { "@type": "Answer", "text": "Limiter la durée de prescription et surveiller l'utilisation sont des mesures préventives." } }, { "@type": "Question", "name": "Quelles sont les recommandations pour l'utilisation des benzazépines ?", "position": 12, "acceptedAnswer": { "@type": "Answer", "text": "Utiliser à la dose minimale efficace et pour la durée la plus courte possible." } }, { "@type": "Question", "name": "Comment éduquer les patients sur les benzazépines ?", "position": 13, "acceptedAnswer": { "@type": "Answer", "text": "Informer sur les risques, les effets secondaires et l'importance du suivi médical." } }, { "@type": "Question", "name": "Quels sont les risques d'auto-médication avec des benzazépines ?", "position": 14, "acceptedAnswer": { "@type": "Answer", "text": "L'auto-médication peut entraîner des surdoses, des dépendances et des interactions médicamenteuses." } }, { "@type": "Question", "name": "Comment réduire l'usage des benzazépines dans la population ?", "position": 15, "acceptedAnswer": { "@type": "Answer", "text": "Promouvoir des alternatives thérapeutiques et sensibiliser aux risques associés." } }, { "@type": "Question", "name": "Comment sont prescrites les benzazépines ?", "position": 16, "acceptedAnswer": { "@type": "Answer", "text": "Elles sont prescrites pour des périodes courtes, généralement moins de 4 semaines." } }, { "@type": "Question", "name": "Quelles alternatives aux benzazépines pour l'anxiété ?", "position": 17, "acceptedAnswer": { "@type": "Answer", "text": "Les antidépresseurs, thérapies cognitives et techniques de relaxation sont des alternatives." } }, { "@type": "Question", "name": "Comment gérer une overdose de benzazépines ?", "position": 18, "acceptedAnswer": { "@type": "Answer", "text": "L'overdose nécessite une attention médicale immédiate, souvent avec des antidotes comme le flumazénil." } }, { "@type": "Question", "name": "Les benzazépines sont-elles efficaces pour l'insomnie ?", "position": 19, "acceptedAnswer": { "@type": "Answer", "text": "Elles sont efficaces à court terme, mais peuvent entraîner une dépendance et des effets secondaires." } }, { "@type": "Question", "name": "Quel suivi est nécessaire lors de l'utilisation de benzazépines ?", "position": 20, "acceptedAnswer": { "@type": "Answer", "text": "Un suivi régulier est essentiel pour évaluer l'efficacité et surveiller les effets secondaires." } }, { "@type": "Question", "name": "Quelles complications peuvent survenir avec les benzazépines ?", "position": 21, "acceptedAnswer": { "@type": "Answer", "text": "Les complications incluent la dépendance, les troubles cognitifs et les accidents liés à la somnolence." } }, { "@type": "Question", "name": "Les benzazépines augmentent-elles le risque de chutes ?", "position": 22, "acceptedAnswer": { "@type": "Answer", "text": "Oui, elles augmentent le risque de chutes, surtout chez les personnes âgées." } }, { "@type": "Question", "name": "Comment les benzazépines affectent-elles la respiration ?", "position": 23, "acceptedAnswer": { "@type": "Answer", "text": "Elles peuvent déprimer le système respiratoire, surtout en cas de surdose." } }, { "@type": "Question", "name": "Les benzazépines peuvent-elles interagir avec d'autres médicaments ?", "position": 24, "acceptedAnswer": { "@type": "Answer", "text": "Oui, elles peuvent interagir avec des opioïdes, des antidépresseurs et d'autres sédatifs." } }, { "@type": "Question", "name": "Quels sont les effets des benzazépines sur la grossesse ?", "position": 25, "acceptedAnswer": { "@type": "Answer", "text": "Elles peuvent causer des malformations congénitales et des complications néonatales." } }, { "@type": "Question", "name": "Quels facteurs augmentent le risque de dépendance aux benzazépines ?", "position": 26, "acceptedAnswer": { "@type": "Answer", "text": "Les antécédents de troubles de l'usage de substances et les troubles mentaux augmentent le risque." } }, { "@type": "Question", "name": "Les personnes âgées sont-elles plus à risque avec les benzazépines ?", "position": 27, "acceptedAnswer": { "@type": "Answer", "text": "Oui, elles sont plus sensibles aux effets sédatifs et aux risques de chutes." } }, { "@type": "Question", "name": "Comment l'usage prolongé de benzazépines affecte-t-il le risque ?", "position": 28, "acceptedAnswer": { "@type": "Answer", "text": "L'usage prolongé augmente le risque de dépendance et de troubles cognitifs." } }, { "@type": "Question", "name": "Quels facteurs psychologiques influencent l'usage des benzazépines ?", "position": 29, "acceptedAnswer": { "@type": "Answer", "text": "L'anxiété, la dépression et le stress peuvent inciter à l'usage des benzazépines." } }, { "@type": "Question", "name": "Les interactions médicamenteuses augmentent-elles les risques ?", "position": 30, "acceptedAnswer": { "@type": "Answer", "text": "Oui, certaines interactions peuvent intensifier les effets sédatifs et augmenter le risque d'accidents." } } ] } ] }
Dr Olivier Menir

Contenu validé par Dr Olivier Menir

Expert en Médecine, Optimisation des Parcours de Soins et Révision Médicale

Validation scientifique effectuée le 09/05/2025

Contenu vérifié selon les dernières recommandations médicales

En savoir plus sur Dr Menir

Sous-catégories

31 au total
└─

Benzodiazépines

Benzodiazepines D001569 - D03.633.100.079.080
└─

Diltiazem

Diltiazem D004110 - D03.633.100.079.150
└─

Fénoldopam

Fenoldopam D018818 - D03.633.100.079.300
└─

Galantamine

Galantamine D005702 - D03.633.100.079.525
└─

Ivabradine

Ivabradine D000077550 - D03.633.100.079.801
└─

1-Phényl-2,3,4,5-tétrahydro-1H-3-benzazépine-7,8-diol

2,3,4,5-Tetrahydro-7,8-dihydroxy-1-phenyl-1H-3-benzazepine D015647 - D03.633.100.079.838
└─

Tolvaptan

Tolvaptan D000077602 - D03.633.100.079.875
└─└─

Alprazolam

Alprazolam D000525 - D03.633.100.079.080.030
└─└─

Benzodiazépinones

Benzodiazepinones D001570 - D03.633.100.079.080.070
└─└─

Chlordiazépoxyde

Chlordiazepoxide D002707 - D03.633.100.079.080.150
└─└─

Clobazam

Clobazam D000078306 - D03.633.100.079.080.165
└─└─

Clorazépate dipotassique

Clorazepate Dipotassium D003009 - D03.633.100.079.080.180
└─└─

Estazolam

Estazolam D004949 - D03.633.100.079.080.250
└─└─

Médazépam

Medazepam D008472 - D03.633.100.079.080.550
└─└─

Midazolam

Midazolam D008874 - D03.633.100.079.080.575
└─└─

Olanzapine

Olanzapine D000077152 - D03.633.100.079.080.738
└─└─

Triazolam

Triazolam D014229 - D03.633.100.079.080.900
└─└─└─

Bromazépam

Bromazepam D001960 - D03.633.100.079.080.070.110
└─└─└─

Clonazépam

Clonazepam D002998 - D03.633.100.079.080.070.150
└─└─└─

Dévazépide

Devazepide D020109 - D03.633.100.079.080.070.200
└─└─└─

Diazépam

Diazepam D003975 - D03.633.100.079.080.070.216
└─└─└─

Flumazénil

Flumazenil D005442 - D03.633.100.079.080.070.305
└─└─└─

Flunitrazépam

Flunitrazepam D005445 - D03.633.100.079.080.070.320
└─└─└─

Flurazépam

Flurazepam D005479 - D03.633.100.079.080.070.348
└─└─└─

Lorazépam

Lorazepam D008140 - D03.633.100.079.080.070.450
└─└─└─

Nitrazépam

Nitrazepam D009567 - D03.633.100.079.080.070.565
└─└─└─

Oxazépam

Oxazepam D010076 - D03.633.100.079.080.070.663
└─└─└─

Pirenzépine

Pirenzepine D010890 - D03.633.100.079.080.070.750
└─└─└─

Prazépam

Prazepam D011222 - D03.633.100.079.080.070.784
└─└─└─

Témazépam

Temazepam D013693 - D03.633.100.079.080.070.880
└─└─└─└─

Nordazépam

Nordazepam D003708 - D03.633.100.079.080.070.216.500

Auteurs principaux

Bernhard Wünsch

9 publications dans cette catégorie

Affiliations :
  • Institute of Pharmaceutical and Medicinal Chemistry, University of Münster, Münster, Germany.
Publications dans "Benzazépines" : Voir toutes les publications (9)

Dirk Schepmann

7 publications dans cette catégorie

Affiliations :
  • Institute of Pharmaceutical and Medicinal Chemistry, University of Münster, Corrensstr. 48, 48149, Münster, Germany.
Publications dans "Benzazépines" : Voir toutes les publications (7)

Simon M Ametamey

5 publications dans cette catégorie

Affiliations :
  • Institute of Pharmaceutical Sciences, ETH Zurich, Zurich, Switzerland simon.ametamey@pharma.ethz.ch.
Publications dans "Benzazépines" :

Nadine Ritter

3 publications dans cette catégorie

Affiliations :
  • Institute for Genetics of Heart Diseases (IfGH), Department of Cardiovascular Medicine, University Hospital Münster, 48149, Münster, Germany. nadine.ritter@uni-muenster.de.
  • Chembion, University of Münster, 48149, Münster, Germany. nadine.ritter@uni-muenster.de.
Publications dans "Benzazépines" :

Guiscard Seebohm

3 publications dans cette catégorie

Affiliations :
  • Institute for Genetics of Heart Diseases (IfGH), Department of Cardiovascular Medicine, University Hospital Münster, 48149, Münster, Germany.
  • Chembion, University of Münster, 48149, Münster, Germany.
Publications dans "Benzazépines" :

Alexander Markus

3 publications dans cette catégorie

Affiliations :
  • Institut für Pharmazeutische und Medizinische Chemie der Universität Münster, Münster, Germany.
Publications dans "Benzazépines" :

Paul Disse

2 publications dans cette catégorie

Affiliations :
  • Institute for Genetics of Heart Diseases (IfGH), Department of Cardiovascular Medicine, University Hospital Münster, 48149, Münster, Germany.
  • Chembion, University of Münster, 48149, Münster, Germany.
Publications dans "Benzazépines" :

Julian A Schreiber

2 publications dans cette catégorie

Affiliations :
  • Institute for Genetics of Heart Diseases (IfGH), Department of Cardiovascular Medicine, University Hospital Münster, 48149, Münster, Germany.
  • Institute of Pharmaceutical and Medicinal Chemistry, University of Münster, Corrensstr. 48, 48149, Münster, Germany.
Publications dans "Benzazépines" :

Nathalie Strutz-Seebohm

2 publications dans cette catégorie

Affiliations :
  • Institute for Genetics of Heart Diseases (IfGH), Department of Cardiovascular Medicine, University Hospital Münster, 48149, Münster, Germany.
Publications dans "Benzazépines" :

Nengneng Zhou

2 publications dans cette catégorie

Affiliations :
  • Key Laboratory of Functionalized Molecular Solids, Ministry of Education, Anhui Key Laboratory of Molecule-Based Materials, College of Chemistry and Materials Science, Anhui Normal University, Wuhu, Anhui 241000, China.
Publications dans "Benzazépines" :

Fangli Zhao

2 publications dans cette catégorie

Affiliations :
  • Key Laboratory of Functionalized Molecular Solids, Ministry of Education, Anhui Key Laboratory of Molecule-Based Materials, College of Chemistry and Materials Science, Anhui Normal University, Wuhu, Anhui 241000, China.
Publications dans "Benzazépines" :

Lei Wang

2 publications dans cette catégorie

Affiliations :
  • Key Laboratory of Functionalized Molecular Solids, Ministry of Education, Anhui Key Laboratory of Molecule-Based Materials, College of Chemistry and Materials Science, Anhui Normal University, Wuhu, Anhui 241000, China.
Publications dans "Benzazépines" :

Xiang Gao

2 publications dans cette catégorie

Affiliations :
  • Key Laboratory of Functionalized Molecular Solids, Ministry of Education, Anhui Key Laboratory of Molecule-Based Materials, College of Chemistry and Materials Science, Anhui Normal University, Wuhu, Anhui 241000, China.
Publications dans "Benzazépines" :

Xiaowei Zhao

2 publications dans cette catégorie

Affiliations :
  • Key Laboratory of Functionalized Molecular Solids, Ministry of Education, Anhui Key Laboratory of Molecule-Based Materials, College of Chemistry and Materials Science, Anhui Normal University, Wuhu, Anhui 241000, China.
Publications dans "Benzazépines" :

Man Zhang

2 publications dans cette catégorie

Affiliations :
  • Key Laboratory of Functionalized Molecular Solids, Ministry of Education, Anhui Key Laboratory of Molecule-Based Materials, College of Chemistry and Materials Science, Anhui Normal University, Wuhu, Anhui 241000, China.
Publications dans "Benzazépines" :

Álvaro Velasco-Rubio

2 publications dans cette catégorie

Affiliations :
  • Centro Singular de Investigación en Química Biolóxica e Materiais Moleculares (CiQUS), Departamento de Química Orgánica, Universidade de Santiago de Compostela, 15782 Santiago de Compostela, Spain.
Publications dans "Benzazépines" :

Jesús A Varela

2 publications dans cette catégorie

Affiliations :
  • Centro Singular de Investigación en Química Biolóxica e Materiais Moleculares (CiQUS), Departamento de Química Orgánica, Universidade de Santiago de Compostela, 15782 Santiago de Compostela, Spain.
Publications dans "Benzazépines" :

Carlos Saá

2 publications dans cette catégorie

Affiliations :
  • Centro Singular de Investigación en Química Biolóxica e Materiais Moleculares (CiQUS), Departamento de Química Orgánica, Universidade de Santiago de Compostela, 15782 Santiago de Compostela, Spain.
Publications dans "Benzazépines" :

Yoshikazu Arai

2 publications dans cette catégorie

Affiliations :
  • End-Organ Disease Laboratories, Daiichi Sankyo Co., Ltd., 1-2-58 Hiromachi, Shinagawa-ku, Tokyo 140-8710, Japan. Electronic address: arai.yoshikazu.mh@daiichisankyo.co.jp.
Publications dans "Benzazépines" :

Yohei Kiyotsuka

2 publications dans cette catégorie

Affiliations :
  • End-Organ Disease Laboratories, Daiichi Sankyo Co., Ltd., 1-2-58 Hiromachi, Shinagawa-ku, Tokyo 140-8710, Japan.
Publications dans "Benzazépines" :

Sources (10000 au total)

Contrast media volume reduction with the DyeVert

10 2023
DOI: 10.1002/ccd.30809 PMID: 37668067

Contrast associated acute kidney injury (CA-AKI) can lead to an increased risk of adverse events. Contrast media (CM) volume reduction has been advocated as a pivotal strategy to prevent CA-AKI in sta... To compare the effectiveness of CM volume reduction with the DyeVert... We prospectively collected data from 136 patients with stable coronary artery disease at high risk of CA-AKI treated with left ventricular end diastolic pressure (LVEDP)- guided hydration and undergoi... Patients in the DyeVert group were treated with a significant lower CM volume (median: 47.5 vs. 84.0 mL, p < 0.001). The trend in creatinine increase was lower (p = 0.004) and the Δ of creatinine (0-4... CM volume reduction with the DyeVert...

Humans Contrast Media Creatinine Treatment Outcome Acute Kidney Injury +4 autres

Strategies for calculating contrast media dose for chest CT.

12 06 2023
DOI: 10.1186/s41747-023-00345-w PMID: 37303003

Total body weight (TBW) is a frequently used contrast media (CM) strategy for dose calculation in enhanced CT, yet it is suboptimal as it lacks consideration of patient characteristics, such as body f... Eighty-nine adult patients referred for CM thoracic CT were retrospectively included, categorized as either normal, muscular, or overweight. Patient body composition data was used to calculate the CM ... BIA demonstrated the highest and lowest calculated CM dose in muscular and overweight groups respectively, compared to other strategies. For the normal group, the lowest calculated CM dose was achieve... The BIA method is more adaptive to variations in patient body habitus especially in muscular and overweight patients and is most closely correlated to patient demographics. This study could support ut... The BIA-based method is adaptive to variations in body habitus especially in muscular and overweight patients and is closely correlated to patient demographics for contrast-enhanced chest CT.... • Calculations based on BIA showed the largest variation in CM dose. • Lean body weight using BIA demonstrated the strongest correlation to patient demographics. • Lean body weight BIA protocol may be...

Adult Humans Contrast Media Overweight Retrospective Studies +2 autres

Impact of iodinated contrast media conserving interventions and lessons for the future.

Feb 2023
DOI: 10.1111/1754-9485.13458 PMID: 35856814

A severe shortage of iodinated contrast medium (ICM) has forced radiology departments around the world to implement strategies to reduce contrast utilization. The aim of this study was to evaluate the... Our radiology department instituted several ICM-conserving interventions on 13... The average daily number of CECT (all), CECT (inpatient and ED), CTPA, CECT AP, and 'Code stroke' CT scans decreased significantly (P < 0.01), by 58.6%, 68.8%, 74.1%, 88.0%, and 37.5%, respectively. T... Interventions in CT alone, focused on improving patient triage to CECT while avoiding deferment of any outpatient oncology studies, have achieved an approximately two-thirds reduction in ICM consumpti...

Humans Contrast Media Tomography, X-Ray Computed Computed Tomography Angiography Angiography +1 autres

Contrast media extravasation injury: a prospective observational cohort study.

25 Oct 2023
DOI: 10.1186/s40001-023-01444-5 PMID: 37880738

To identify the risk factors for moderate and severe contrast media extravasation and provide effective guidance to reduce the degree of extravasation injuries.... We observed 224 adult patients who underwent contrast media extravasation at Xiangya Hospital of Central South University, Hunan Provincial Maternal and Child Healthcare Hospital, and Xiangya Changde ... Among 224 patients, 0 (0%) had severe, 18 (8.0%) had moderate, and 206 (92.0%) had mild contrast media extravasation injury. Multivariate logistic regression analysis revealed malignant tumors (odds r... Risk factors for moderate contrast media extravasation injury are malignant tumors, iohexol, large-volume (> 50 mL) extravasation, and back-of-the-hand injection. Analysis of these risk factors can he... High-risk patients with extravasation support should choose the appropriate contrast media type, avoiding back-of-the-hand injections. We recommend that patients with cancer be implanted with a high-p...

Adult Humans Contrast Media Extravasation of Diagnostic and Therapeutic Materials Iohexol +3 autres

[The atorvastatin effects on the prevention of contrast-induced acute kidney injury during computed tomography with contrast media].

24 Oct 2022
DOI: 10.26442/0403660.2022.09.201845 PMID: 36286755

To assess the role of atorvastatin to the frequency of contrast-induced acute kidney injury (CI-AKI) in patients with cardiovascular diseases (CVD) undergoing computed tomography (CT) with intravenous... One hundred patients with CVD undergoing CT with with intravenous contrast media administration were included in prospective observational study (ClinicalTrials.gov ID NCT04666389). Patients were divi... CI-AKI was diagnosed in 4 (3.96%) patients. At the same time, it was not possible to establish statistically significant relationships (p0.05) between risk factors and the development of CI-AKI. Stati... Cardiovascular diseases may increase the risk of CI-AKI after computed tomography with intravenous contrast media administration. Therefore, it is recommended to evaluate the serum creatinine concentr...

Male Humans Middle Aged Atorvastatin Contrast Media +6 autres

Imaging human lung perfusion with contrast media: A meta-analysis.

Jul 2023
DOI: 10.1016/j.ejrad.2023.110850 PMID: 37178490

To pool and summarise published data of pulmonary blood flow (PBF), pulmonary blood volume (PBV) and mean transit time (MTT) of the human lung, obtained with perfusion MRI or CT to provide reliable re... PubMed was systematically searched to identify studies that quantified PBF/PBV/MTT in the human lung by injection of contrast agent, imaged by MRI or CT. Only data analysed by 'indicator dilution theo... PBV was obtained from 313 measurements from 14 publications (wM: 13.97 ml/100 ml, wSD: 4.21 ml/100 ml, wCoV 0.30). MTT was obtained from 188 measurements from 10 publications (wM: 5.91 s, wSD: 1.84 s ... Reference values for PBF, MTT and PBV were obtained in HV. The literature data are insufficient to draw strong conclusions regarding disease reference values....

Humans Contrast Media Lung Pulmonary Circulation Magnetic Resonance Imaging +1 autres